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Christian Lampl1*, Rigmor Jensen2, Paolo Martelletti3 and Dimos-Dimitrios Mitsikostas4In the past years a unifying definition of refractory head-
ache (rH) has been extensively discussed [1,2] but, to date,
has not been agreed upon. It is widely agreed, that refrac-
toriness, for whatever category and disease, implies a high
burden with tremendous impact in health related quality
of life (HRQoL) [3]. Despite that fact, an overall accepted
definition of rH would be more than important for man-
aging and triaging patients to an appropriate level of care
and for determining eligibility for epidemiological and
clinical studies.
So far, there are different and non-conclusive categories
that try to describe refractoriness. In the understanding of
refractoriness particular in headache patients several
important issues have to be addressed: First, it is of
importance to emphasize the difficulty that refractoriness
in headache may just represent more or less treatable ver-
sion(s) of many different disorders, rather than a unique
disease or group of disorders. Second, the same patient
might be identified as refractory at one time, but treat-
ment responsive at another. Therefore it may be of crucial
importance to evaluate acute and prophylactic treatment
response, baseline headache severity, partial response ver-
sus an all-or-none response, and the possibility of any
variability in the treatment response over time for each
headache disorder and patient from the very first on.
Some evidence supports the hypothesis that baseline
headache attack intensity has an impact on determination
of treatment response [4]. It may also be hypothesized that
patients with high baseline headache frequency were more
likely to be drug resistant, meaning that it is harder to
eradicate many headache attacks than a few. Without
recording baseline frequency and severity rate, it is almost
impossible to know whether there has been partial or no
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fore severity of headache and frequency of disease can be
determined. When headache attacks are not completely
controlled, the conclusion may be that the administered
drug is not effective and that the patient therefore is “re-
sistant”. Third, as in other conditions [5] the definition of
responder or non-responder enormously differs among
both clinicians and investigators.
All these considerations lead to variability in clinical and
epidemiological research results, both being of importance
to increase our knowledge in the understanding of rH.
What are the critical issues so far: (i) there is no standard-
ized definition of rH; (ii) at the time of first diagnosis
headache patients do not necessarily become refractory
immediately, nor do they mandatorily remain refractory
throughout the course of their disease; (iii) due to the ne-
cessity that most patients should be treated rapidly after
diagnosis response to medication often is assessed without
a pretreatment baseline and it remains unclear whether or
not so-called refractory patients have had a substantial re-
sponse to treatment; (iv) headache pain and associated
symptoms are frequently intermittent, making this disease
different from others that have been examined for treat-
ment resistance; (v) the natural history is not known.
For all these purposes the Board of the European Head-
ache Federation (EHF) felt the need to develop new con-
sensus criteria that define refractory chronic migraine
(rCM) and refractory chronic cluster headache (rCCH).
These new definitions of rCM and rCCH, which were
agreed upon within the EHF, allows us to separate patients
into categories of refractory and non-refractory, being im-
portant for clinicians, clinical and epidemiological trials.
The EHF is aware of that still many challenges are on
the road in identifying which patients are really treatment
resistant and to what degree. It is a misconception that a
patient necessarily will fall into one of the two categories
and stay there. From a clinical perspective a large number
of patients may fit each category for periods of time. Butn Open Access article distributed under the terms of the Creative Commons
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to responsive and the opposite. E.g. after neuromodula-
tion, many patients will become headache free but have to
continue with prophylactic medication to prevent head-
ache recurrence. These patients have shifted from being
treatment resistant to being treatment sensitive.
To define treatment response - EHF claims the need to
go into patient categorization - one term does not fit all.
We badly need the same definitions of rH, better informa-
tion about pretreatment headache rate and severity, more
precise information about prior acute and prophylactic
treatment response and scientific data regarding the nat-
ural history of drug response.
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